ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
23 announcements with these filters
Q2FY27 revenue ₹23.29 Cr (-23% YoY, +62% QoQ), EBITDA margin 16.9%, PAT ₹1.63 Cr (-67% YoY). Sequential recovery; CRAMS and new products progressing.
Shree Ganesh Remedies released a press release on Q2 and H1 FY27 unaudited results, with Q2 revenue of ₹23.29 Crore, down 23% year-on-year. PAT fell 67% to ₹1.63 Crore.
Shree Ganesh Remedies' board approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Revenue from operations for the half year was Rs 3,765.47 lakhs, down from Rs 5,498.29 lakhs a year earlier.
Shree Ganesh Remedies Ltd notified BSE of a board meeting on October 31, 2026, to consider unaudited standalone and consolidated results for the quarter ended September 2026. Trading window remains closed until 48 hours after the results declaration.
Shree Ganesh Remedies Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Shree Ganesh Remedies Ltd has announced the resignation of Mr. Aditya Vikrambhai Patel as Company Secretary and the appointment of Ms. Akanksha as his successor.
Shree Ganesh Remedies held its 31st Annual General Meeting on September 12, 2026. The meeting transacted ordinary and special business items, including director and auditor appointments.
Shree Ganesh Remedies Limited has issued the notice for its 31st Annual General Meeting scheduled for September 12, 2026. Shareholders will consider key resolutions and director appointments.
Shree Ganesh Remedies Limited has filed its Annual Report for FY 2025-26. It also includes the notice for the 31st Annual General Meeting on September 12, 2026.
Q1FY27 was challenging with Revenue/PAT declining 42%/68% YoY due to subdued European demand and termination of a distributor agreement. Management shifted focus to direct customer engagement and CRAMS projects.
Shree Ganesh Remedies announced its Q1FY27 financial results. Revenue from operations stood at ₹14.36 Crore, with a PAT of ₹1.12 Crore.
Shree Ganesh Remedies Limited has appointed M/s. M. I. Prajapati & Associates LLP as the company's Cost Auditor for a term of 12 months.
Shree Ganesh Remedies Ltd reported revenue from operations of ₹14.4 Cr (-41.7% YoY) and net profit of ₹1.1 Cr (-67.6% YoY) for Q1 FY27.
Shree Ganesh Remedies Ltd has scheduled a Board Meeting for August 12, 2026, to consider and approve the financial results for the quarter ended June 30, 2026.
Shree Ganesh Remedies Ltd filed its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with regulatory requirements.
Shree Ganesh Remedies appointed Ms. Hiral Ankitkumar Shah as Additional Non-Executive Independent Director. The appointment is effective July 17, 2026, for a five-year term.
Shree Ganesh Remedies clarified that recent share price movements are market-driven. The company confirms all necessary disclosures have been made to exchanges.
Shree Ganesh Remedies filed its Annual Secretarial Compliance Report for FY2026. The auditor noted a prior ₹0.00 Crore fine for delayed results submission in 2024.
Shree Ganesh Remedies reported Q4 FY26 revenue of INR 33.20 cr (up 36% YoY). Management characterized FY26 as a consolidation year, focusing on CRAMS pilot trials and capacity expansion.
Management characterized FY26 as a consolidation year, focusing on groundwork for CRAMS. While Q4 showed strong sequential recovery, full-year growth remained flat as the company pivoted from generic domestic markets to specialized global molecules.
Shree Ganesh Remedies reported stagnant FY26 revenue of ₹109.3cr with a 23% PAT decline to ₹17.8cr. Focus remains on scaling CRAMS and specialty chemicals via expansion.
Shree Ganesh Remedies Ltd reported revenue from operations of ₹33.2 Cr (+36.1% YoY) and net profit of ₹6.3 Cr (-4.5% YoY) for Q4 FY26.
Shree Ganesh Remedies reported its FY 2025-26 audited financial results alongside auditor reports. The board also re-appointed M/s. S N D K & Associates as internal auditors.